Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cells show promise for failing livers

NCT ID NCT06242405

Disease control Sponsor: General Hospital of Shenyang Military Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether multiple infusions of stem cells from donated umbilical cords could help people with end-stage liver disease. 92 adults received the stem cells through a vein, and researchers tracked liver function and complications. The goal was to see if repeated doses work better than a single dose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
umbilical cord mesenchymal stem cells
What this could lead to
If successful, this could point toward a way to improve liver function and reduce complications in people with end-stage liver disease, potentially delaying the need for a transplant.
What could go wrong
This is a small, completed study with 92 participants and no control group, so results may not be conclusive. Stem cell infusions carry risks like infection or immune reactions, and the long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

92 people

The number who actually took part.

Started

Mar 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. 18-80 years old * 2\. End-stage liver disease * 3\. Signed informed consent Exclusion Criteria: * 1\. Tumours of the liver or other organs * 2\. Liver transplantation recipients * 3\. Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases * 4\. Other diseases that may seriously affect the survival * 5\. Human immunodeficiency syndrome * 6\. Interferon or glucocorticoid therapy within 1 year * 7\. Treated for mental illness * 8\. Participation in other clinical trials within 30 days * 9\. Pregnant or breastfeeding subjects * 10\. Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies * 11\. Other circumstances that are unsuitable for participation in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic liver failure End Stage Liver Disease Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage liver disease

Contacts and locations

Locations

  • General Hospital of Northern Theater Command

    Shenyang, Liaoning, 110840, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.